Recently, the advent of antibody-drug conjugates (ADC), a class of therapeutic compounds designed to deliver cytotoxic agents selectively to tumor cells, has renewed hope for antibody-based therapy for HER2-mutant NSCLC. Here, ERBB2 is linked to non-small cell lung carcinoma.